Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections

Phathom Pharmaceuticals, Inc. Reports Smaller-Than-Expected Quarterly Loss

Phathom Pharmaceuticals, Inc. (PHAT) announced a quarterly net loss of $0.08 per share, which was slightly better than the consensus forecast of a $0.09 loss. In comparison, the company reported a loss of $0.79 per share in the same period last year. These results exclude one-time items.

This performance resulted in an earnings surprise of 11.11%. In the previous quarter, the company was anticipated to post a $0.30 per share loss but instead reported a loss of $0.15, exceeding expectations by 50%.

Over the past year, Phathom Pharmaceuticals has outperformed consensus earnings per share estimates in two out of four quarters.

Operating within the Medical - Biomedical and Genetics sector, Phathom Pharmaceuticals generated $57.58 million in revenue for the quarter ending December 2025, surpassing analyst projections by 0.29%. This marks a significant increase from the $29.66 million reported a year earlier. The company has exceeded revenue expectations in each of the last four quarters.

How the stock reacts in the near term will largely depend on management’s insights during the earnings call and their outlook for future performance.

Since the start of the year, Phathom Pharmaceuticals’ share price has declined by approximately 25.7%, while the S&P 500 has gained 1.5% over the same period.

What Lies Ahead for Phathom Pharmaceuticals?

Despite lagging behind the broader market this year, investors are now considering the future prospects for Phathom Pharmaceuticals (PHAT).

One of the most reliable indicators for a stock’s future direction is its earnings outlook, which includes both current consensus forecasts for upcoming quarters and any recent changes to those estimates.

Studies have shown that short-term stock price movements are closely tied to trends in earnings estimate revisions. Investors can monitor these changes themselves or use established tools like the Zacks Rank, which has a strong track record of leveraging earnings estimate trends.

Prior to this earnings announcement, analyst estimate revisions for Phathom Pharmaceuticals were negative. Although these estimates may shift following the latest results, the current Zacks Rank for the stock is #4 (Sell), suggesting the shares may underperform the market in the near term.

It remains to be seen how analyst estimates for the next quarters and the current fiscal year will evolve. At present, the consensus forecast is a loss of $0.12 per share on $59.93 million in revenue for the upcoming quarter, and earnings of $0.23 per share on $315.76 million in revenue for the full year.

Investors should also consider the overall industry outlook, as it can significantly influence individual stock performance. The Medical - Biomedical and Genetics industry currently ranks in the top 36% of over 250 Zacks-tracked industries. Historically, the top half of Zacks-ranked industries outperform the bottom half by more than two to one.

Industry Peers: Coherus Oncology Update

Another company in the same sector, Coherus Oncology (CHRS), has yet to release its results for the quarter ending December 2025.

Coherus Oncology is expected to report a quarterly loss of $0.31 per share, reflecting a 10.7% decrease compared to the previous year. The consensus earnings estimate for this period has remained unchanged over the past month.

Revenue for Coherus Oncology is projected to be $13.12 million, representing a 75.8% decline from the same quarter last year.

Is Phathom Pharmaceuticals, Inc. (PHAT) a Good Investment?

Thinking about investing in Phathom Pharmaceuticals, Inc. (PHAT)? For a look at the top stocks to consider over the next month, check out Zacks Investment Research’s free report.

Since 1978, Zacks Investment Research has provided investors with independent research and analytical tools. Over the past 25 years, their Zacks Rank stock-rating system has delivered an average annual return of 24.08%, more than doubling the S&P 500’s performance between January 1, 1988 and May 6, 2024.

Want more recommendations from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days for free.